CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics DGX, +1.23{20b543310651bf6f3679f07daa0e532ca50e05ab066d8bcfc12d35f979f65272} the world’s leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD).

CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

Scroll to Top